Novartis $12bn bet on Avidity well placed after mid-stage FSHD win
Novartis’ $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company’s lead assets, delpacibart braxlosiran …
Post
-
-
MAIA Biotechnology opens second US site for THIO-101 trial
MAIA Biotechnology has opened enrolment at a second clinical site in the US for its THIO-101 Phase II expansion trial, …
-
CONNECTA Therapeutics begins Phase IIa trial of CTH120 for FXS
CONNECTA Therapeutics has commenced a Phase IIa trial to assess its lead programme, CTH120, a neuroplasticity modulator, in male adults …
-
Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to …
-
Sanofi terminates Phase III CIDP trial due to low efficacy
Sanofi is terminating a Phase III chronic inflammatory demyelinating polyneuropathy (CIDP) trial of riliprubart after analysis showed the drug is …
-
CONNECTA Therapeutics begins Phase IIa trial of CTH120 for FXS
CONNECTA Therapeutics has commenced a Phase IIa trial to assess its lead programme, CTH120, a neuroplasticity modulator, in male adults …
-
Enhance clinical trial screening and improve patient matching accuracy
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to …
-
Sanofi terminates Phase III CIDP trial due to low efficacy
Sanofi is terminating a Phase III chronic inflammatory demyelinating polyneuropathy (CIDP) trial of riliprubart after analysis showed the drug is …
-
Alpha Cognition announces top-line data in BEACON study for Alzheimer’s
Alpha Cognition has reported positive top line data from the BEACON real-world study assessing provider-reported outcomes for long-term care residents …
-
Windward Bio doses first patients in Phase II SIRIUS COPD trial
Harbour BioMed’s partner Windward Bio has dosed the first patients in the Phase II SIRIUS trial with HBM9378/WIN378 (SKB378), a fully …
-
ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering
This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety and …
-
ADA26: Early data for teplizumab demonstrates promise for slowing T1D progression
During the 2026 American Diabetes Association (ECO) Scientific Sessions in New Orleans, a real-world cohort of type 1 diabetic (T1D) …
-
Study explores gaps in Europe’s steatotic liver disease response plans
The growing prevalence of metabolic dysfunction-associated steatotic liver disease and non-alcoholic steatotic hepatitis (MASLD/NASH) poses a growing public health risk, …
-
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials
Gilead Sciences and MSD’s human immunodeficiency virus (HIV) once weekly tablet combination has met primary endpoints in two Phase III …
-
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
AstraZeneca has unveiled data from two Phase IIb trials of its in-licensed oral glucagon-like peptide-1 receptor agonist (GLP-1RA), touting a …
